VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
nasal Tetracosactide
Phase 2
Peptide
H
Hospices Civils de Lyon
1
Indications
2
Total Trials
1
Active Trials
0
Competitors
Clinical
Trials by Indication
[1]
ESS
1 trial
NeSST2: The Development of a Noninvasive Short Synacthen Test
Recruiting
·
S
Sheffield Children's NHS Foundation Trust
·
Phase 2
·
NCT03514589
·
12 enrolled
Headache
1 trial
Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)
Terminated
·
H
Hospices Civils de Lyon
·
Phase 2
·
NCT02813655
·
46 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
2 trial records for nasal Tetracosactide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
nasal Tetracosactide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for nasal Tetracosactide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Hospices Civils de Lyon company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Peptide
[2]
Highest Phase
Phase 2
[1]
Company
H
Hospices Civils de Lyon
Related News